Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia

Matsuda, A; Jinnai, I; Yagasaki, F; Kusumoto, S; Minamihisamatsu, M; Honda, S; Murohashi, I; Bessho, M; Hirashima, K
April 1998
Leukemia (08876924);Apr98, Vol. 12 Issue 4, p482
Academic Journal
Refractory anemia (RA) in myelodysplastic syndromes (MDS) are very heterogeneous diseases regarding their morphology, clinical features and survival. We proposed the new designations 'RA with severe dysplasia (RASD)' and 'RA with minimal dysplasia (RAminiD)'. In our criteria, RASD is considered present if a bone marrow (BM) examination shows Pseudo-Pelger-Huet anomalies of mature neutrophils ≥3% and/or micromegakaryocytes (mMgk) of megakaryocytes ≥10% in RA patients. RAminiD is defined as RA cases other than RASD. After the reclassification of 58 primary RA patients, the group was composed of 45 RAminiD and 13 RASD patients. The blast percentage in the BM and the frequency of cytogenetic abnormalities observed in the RASD patients were intermediate between those in the RAminiD and RAEB patients. The analysis of survival curves revealed differences among the three groups; the RASD patients had lower survival probabilities than those of the RAminiD group, and significantly higher probabilities than those of the RAEB group. (RAminiD vs RASD, P = 0.06; RASD vs RAEB, P = 0.004.) Our data indicate that in RA patients, RASD is a distinct subset of RA with an unfavorable clinical outcome.


Related Articles

  • Spontaneous remission from RAEB in a child. De Simone, A; Cantù Rajnoldi, A; Sainati, L; D’Avanzo, M; Allen, M; Maserati, E; Pasquali, F; Aricò, M // Leukemia (08876924);May2001, Vol. 15 Issue 5, p856 

    Focuses on studies regarding the diagnosis of refractory anemia with excessive blasts (RAEB), a category of myelodysplastic syndromes. Presentation of main features of RAEB; Therapeutic measures available for RAEB; Description of case study of a child patient diagnosed with RAEB.

  • New system for assessing the prognosis of refractory anemia patients. Matsuda, A; Jinnai, I; Yagasaki, F; Kusumoto, S; Murohashi, I; Bessho, M; Hirashima, K; Honda, S; Minamihisamatsu, M; Fuchigami, K; Matsuo, T; Kuriyama, K; Tomonaga, M // Leukemia (08876924);Nov99, Vol. 13 Issue 11, p1727 

    Refractory anemia (RA) is a very heterogeneous disease regarding biological and clinical features. The International Prognostic Scoring System (IPSS) was useful for assessing the prognosis in the whole group of 219 myelodysplastic syndrome (MDS) patients. However, the IPSS was not sufficient in...

  • A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Rosenfeld, C.; List, A. // Leukemia (08876924);Jan2000, Vol. 14 Issue 1, p2 

    To guide development of new clinical strategies, a review of recent investigations in the pathobiology of MDS was performed. Articles were identified through a Medline search. Studies, including reviews, are cited in the references. A multistep pathogenesis is proposed. (1) Targeted injury or...

  • More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Hub, Y.O.; Jilani, I.; Estey, E.; Giles, F.; Kantarjian, H.; Albitar, M. // Leukemia (08876924);Nov2002, Vol. 16 Issue 11, p2249 

    Investigates the difference in apoptosis between refractory anemia with excess blasts in transformation, acute myeloid leukemia, and other categories of myelodysplastic syndrome. Analysis of fresh bone marrow samples using the Annexin V and mitochondrial potential assays; Measurement of...

  • The incidence of myelodysplastic syndromes in Western Greece is increasing. Avgerinou, Christina; Alamanos, Yannis; Zikos, Panagiotis; Lampropoulou, Polyxeni; Melachrinou, Maria; Labropoulou, Vassiliki; Tavernarakis, Ioannis; Aktypi, Anthi; Kaiafas, Panagiotis; Raptis, Christos; Kouraklis, Alexandra; Karakantza, Marina; Symeonidis, Argiris // Annals of Hematology;Jul2013, Vol. 92 Issue 7, p877 

    Descriptive epidemiology of the myelodysplastic syndromes (MDS) is always interesting and may reveal time-dependent and geographical variations, as well as occupational exposure. Epidemiological data in Greece are not available by now. We have collected and analyzed medical records of all...

  • PP2A: the Achilles heal in MDS with 5q deletion. Sallman, David A.; ShengWei; Alan List // Frontiers in Oncology;Sep2014, Vol. 4, p1 

    Myelodysplastic syndromes (MDS) represent a hematologically diverse group of myeloid neoplasms, however, one subtype characterized by an isolated deletion of chromosome 5q [del(5q)] is pathologically and clinically distinct. Patients with del(5q) MDS share biological features that account for...

  • Good response to cyclosporine therapy in patients with myelodysplastic syndrromes having the HLA-DRB1*1501 allele. Okamoto, T; Okada, M; Yamada, S; Takatsuka, H; Wada, H; Tamura, A; Fujimora, Y; Takemoto, Y; Kakishita, E // Leukemia (08876924);Feb2000, Vol. 14 Issue 2, p344 

    Focuses on the role of cyclosporine therapy in patients with myelodysplastic syndromes (MDS) having the HLA-DRB1*501 allele. Origin of myelodysplastic syndromes; Immunosuppressive therapies used for the treatment of cytopenia of hypoplastic MDS; Treatment provided to the patients with...

  • Elevated plasma level of differentiation inhibitory factor nm23-H1 protein correlates with risk factors for myelodysplastic syndrome. Ito, Y.; Okabe-Kado; Honma, Y.; Iwase, O.; Shimamoto, T.; Ohyashiki, J.H.; Ohyashiki, K. // Leukemia (08876924);Feb2002, Vol. 16 Issue 2, p165 

    We measured plasma nm23-H1 level (nm23-H1), a differentiation inhibitory factor, by an enzyme-linked immunosorbent assay (ELISA) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS). The nm23-H1 in AA was not significantly elevated when compared to normal subjects (6.66 ±...

  • Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Yazji, S.; Giles, F. J.; Tsimberidou, A-M.; Estey, E.H; Kantarjian, H. M.; O'Brien, S. A.; Kurzrock, R. // Leukemia (08876924);Nov2003, Vol. 17 Issue 11, p2101 

    The purpose of this study was to determine the efficacy of and tolerance to antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndrome (MDS). Therapy consisted of ATG 40?mg/kg/day daily intravenously (i.v.) for 4 days; cyclosporine daily orally for 6 months with levels...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics